January 06, 2022
Weil advised Magellan Health, a Fortune 500 company and a leader in managing the fastest growing, most complex areas of health, including special populations, complete pharmacy benefits and other specialty areas of healthcare, in its $2.2 billion merger with Centene Corporation, a Fortune 50 company and leading multinational healthcare enterprise that provides fully integrated, high-quality, and cost-effective services to government-sponsored and commercial healthcare programs, focusing on under-insured and uninsured individuals. The transaction closed on January 06, 2022.
The Weil team that advised Magellan Health was led by Mergers & Acquisitions partners Raymond Gietz and included Mergers & Acquisitions counsel Rachel Shapiro and Mergers & Acquisitions associates Chelsea Berry, Michael Block and Jason Klig. The team also included Tax partner Helyn Goldstein; Executive Compensation & Benefits partner Amy Rubin; Public Company Advisory Group partner Adé Heyliger; Antitrust counsel Alexis Brown-Reilly and Rob Meyer; Banking & Finance partner Danek Freeman; Banking & Finance associate H.T. Flanagan (Admitted in New York Only); Capital Markets partner Corey Chivers; Technology & IP Transactions Co-Head Jeffrey Osterman; Technology & IP Transactions/Privacy counsel Olivia Greer; Technology & IP Transactions/Privacy associates Kane Wishart and Caleb Small; Regulatory Transactions counsel John O’Loughlin; and Employment Litigation associate Omar Abdel-Hamid (Not Yet Admitted in New York).